65th ASH Annual Meeting & Exposition: 618. Acute Lymphoblastic Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis: Targeted Therapies and The Immune Microenvironment

Symposia: Acute Lymphoblastic Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis Oral and Poster Abstracts
Oral

Research, Fundamental Science, Lymphoid Leukemias, ALL, Biological therapies, Translational Research, Bispecific Antibody Therapy, Non-Biological therapies, Chimeric Antigen Receptor (CAR)-T Cell Therapies, Chemotherapy, genomics, Diseases, immune mechanism, Therapies, immunology, Lymphoid Malignancies, Biological Processes, molecular biology, Minimal Residual Disease

Grand Hall D (Manchester Grand Hyatt San Diego)

Moderators:

Luca Lo Nigro, MD, Azienda Policlinico OVE - Center of Pediatric Hematology Oncology and Marlise R. Luskin, MD, Dana-Farber Cancer Institute

Disclosures:

Lo Nigro: Clinigen: Consultancy, Membership on an entity's Board of Directors or advisory committees; Jazz Pharmaceutical: Consultancy, Membership on an entity's Board of Directors or advisory committees; Amgen: Consultancy, Membership on an entity's Board of Directors or advisory committees; Novartis: Consultancy, Membership on an entity's Board of Directors or advisory committees. Luskin: Novartis: Honoraria; Novartis: Research Funding; Pfizer: Honoraria; Jazz: Honoraria; AbbVie: Research Funding.

4:30 PM

595

In-Depth Immune Profiling in Children with BCP-ALL within the AIEOP-BFM ALL 2017 Study

Anna Laqua¹^*, Hartmann Raifer²^*, Miriam Kelm¹^*, Johanna Horns¹^*, Arunabh Sharma³^*, Anja Möricke⁴^*, Michaela Vossen-Gajcy⁴^*, Julia Alten⁴^*, Lena Fischer-Riepe⁵^*, Bianca Altvater⁵^*, Mahdi Rasa⁶^*, Britta Kehden¹^*, Constantin Proske¹^*, Jan Kässens¹^*, Thomas Beder¹^*, Sonja Bendig^1,7^*, Nadine Wolgast^1,7^*, Lorenz Bastian^1,7^*, Matthias Ritgen¹^*, Magdalena Huber²^*, Astrid Dempfle³^*, Claudia D Baldus, MD^1,7^*, Gunnar Cario, MD^4,7^*, Martin Schrappe, MD^7,8, Claudia Rossig, MD⁹, Monika Brüggemann^1,7^* and Guranda Chitadze^1,7^*

¹Medical Department II, University Cancer Center Schleswig-Holstein, University Medical Center Schleswig-Holstein, Campus Kiel, Kiel, Germany
²Core-Facility Flow Cytometry, Philipps University Marburg, Marburg, Germany
³Institute for Medical Informatics and Statistics, University Hospital Schleswig-Holstein, Kiel, Germany
⁴Department of Pediatrics I, Pediatric Hematology and Oncology, ALL-BFM Study Group, University Medical Center Schleswig-Holstein, Campus Kiel, Kiel, Germany
⁵Department of Pediatric Hematology and Oncology, University Children's Hospital Muenster, Münster, Germany
⁶Institute of Immunology, University Hospital Schleswig-Holstein, Kiel, Germany
⁷Clinical Research Unit CATCH ALL (KFO 5010/1) funded by the Deutsche Forschungsgemeinschaft, Kiel, Germany
⁸Department of Pediatrics I, Pediatric Haematology/Oncology, ALL-BFM Study Group, University Medical Center Schleswig-Holstein, Campus Kiel, Kiel, Germany
⁹Department of Pediatric Hematology and Oncology, University Children's Hospital Muenster, Muenster, Germany

4:45 PM

596

The Impact of Age and Genomics on Drug Sensitivity in 1,076 Children and Adults with B-Cell Acute Lymphoblastic Leukemia

Satoshi Yoshimura, MD¹^*, Zhenhua Li, PhD¹, Yoshihiro Gocho, MD, PhD¹^*, Wenjian Yang, PhD¹^*, Kristine R Crews, PharmD¹^*, Shawn H.R. Lee, MD¹^*, Kathryn G. Roberts, PhD²^*, Charles G. Mullighan, MBBS, MD², Mary V. Relling, PharmD¹^*, Federico Antillon-Klussmann, MD, PhD³, Allen Eng Juh Yeoh, MD⁴, Mignon L. Loh, MD⁵, Mark R. Litzow, MD⁶, Sima Jeha, MD⁷, Seth E. Karol, MD⁸, Hiroto Inaba, MD, PhD⁹, Ching-Hon Pui, MD⁹, Marina Y. Konopleva¹⁰, Nitin Jain, MD¹¹, Wendy Stock, MD¹², Elisabeth Paietta, PhD¹³^*, Elias Jabbour¹¹, Steven M. Kornblau, MD¹¹, William E. Evans, PharmD¹^* and Jun J. J. Yang, PhD^9,14

¹Department of Pharmacy and Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, TN
²Department of Pathology, St. Jude Children's Research Hospital, Memphis, TN
³National Pediatric Oncology Unit, Guatemala City, GTM
⁴National University Health System, Singapore, Singapore
⁵Ben Towne Center for Childhood Cancer Research, Seattle Children’s Hospital, Seattle, WA
⁶Division of Hematology, Mayo Clinic, Rochester, MN
⁷Department of Global Pediatric Medicine, St. Jude Children's Research Hospital, Memphis, TN
⁸Department of Oncology, St Jude Children's Research Hospital, Memphis, TN
⁹Department of Oncology, St. Jude Children's Research Hospital, Memphis, TN
¹⁰Department of Oncology, Montefiore Medical Center and Albert Einstein College of Medicine, Bronx, NY
¹¹Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
¹²Section of Hematology/Oncology, Department of Medicine, University of Chicago, Chicago, IL
¹³Montefiore Medical Ctr. North Div, Bronx, NY
¹⁴Department of Pharmacy and Pharmaceutical Sciences, St. Jude Children's Research Hospital, MEMPHIS, TN

5:00 PM

597

A Specialized CD4+ T-Cell Subset Protects Residual Leukemic Cells from Immune Surveillance, Enabling Relapse

Sean Tracy, MD, PhD¹, Hrishi Venkatesh²^*, Todd P. Knutson³^*, Yinjie Qiu, PhD³^* and Michael A. Farrar, PhD⁴

¹Center for Immunology and Division of Hematology, Oncology, and Transplantation, University of Minnesota, Saint Paul, MN
²Center for Immunology, University of Minnesota, Minneapolis, MN
³Minnesota Supercomputing Institute, University of Minnesota, Minneapolis, MN
⁴Center for Immunology and Department of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, MN

5:15 PM

598

Loss of p53 Impairs Death Receptor Expression and Confers Resistance to CD19-Directed CAR T-Cell Therapy in B-Cell Precursor Acute Lymphoblastic Leukemia

Willem P. J. Cox, MSc^*, Noel M. M. Dautzenberg, MSc.^*, Linde Dekker, MSc^*, Tesa Klenovšek, MSc.^*, Marliek van Hoesel, BSc.^*, Gawin R. Stoll, MSc^*, Roland P. Kuiper, PhD, Laurens T. van der Meer, PhD^*, Friso G. J. Calkoen, MD, Stefan Nierkens, PhD^* and Frank N. van Leeuwen, PhD

Princess Maxima Center for Pediatric Oncology, Utrecht, Netherlands

5:30 PM

599

Unraveling the Mechanism of Action of Bispecific T-Cell Engagers in B-Cell Acute Lymphoblastic Leukemia Using Advanced Single-Cell Multiomics

Anna Gurevich Shapiro, MD, MPhil^1,2,3^*, Eitan Winter, MSc¹^*, Yakir Moshe, MD, PhD^3,4^*, Yonatan Katzenelenbogen, PhD¹^*, Diego Jaitin, PhD¹^*, Mor Zada, MSc¹^*, Oren Barboy, MSc¹^*, Ido Yofe, PhD¹^*, Paulina Chalan, PhD¹^*, San Truong Phan, PhD¹^*, Amir Giladi, PhD^5,6^*, Michael Shapiro, MD MSc^3,7^*, Renana Robinson, MD^3,8^*, Eitan Kugler^3,8^*, Ofir Wolach, MD^8,9^*, Irit Avivi Mazza, MD^3,4^* and Ido Amit, PhD¹^*

¹Department of Systems Immunology, Weizmann Institute of Science, Rehovot, Israel
²Department of Systems Immunology, Weizmann Institute of Science, Tel Aviv, AL, Israel
³Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
⁴Division of Hematology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel
⁵Oncode Institute, Utrecht, Netherlands
⁶Royal Netherlands Academy of Arts and Sciences, Hubrecht Institute, Utrecht, Netherlands
⁷Department of Internal Medicine T, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel
⁸Institute of Hematology, Davidoff Cancer Center, Rabin Medical Center, Petah-Tikva, Israel
⁹Rabin Medical Center, Institute of Hematology, Davidoff Cancer Center, Petah Tikva, Israel

5:45 PM

600

Single-Cell Transcriptomic Profiling of T Cells from Blinatumomab-Treated Patients with B-Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL) Reveals Circulating CD8 T Cell Subsets Associated with Treatment Response

Francesco Corrado, MD^1,2^*, Jan Wulf²^*, Tobias Straub, Ph.D.³^*, Daniel Nixdorf, MSc^2,4^*, Anetta Marcinek, M.Sc.^2,4^*, Nora Philipp^2,4^*, Chang-Feng Chu⁵^*, Christina Zielinski⁵^*, Michael von Bergwelt-Baildon^4,6^*, Viktoria Blumenberg, MD^2,4,6, Maryam Kazerani, Ph.D.^2,4^*, Marion Subklewe, MD^2,6,7 and Veit L. Buecklein, MD^2,4^*

¹Department of Biomedical Sciences, Humanitas University, Pieve Emanuele,Milan, Italy
²Laboratory for Translational Cancer Immunology, Gene Center, LMU Munich, Munich, Germany
³Core Facility Bioinformatics, LMU Biomedical Center, LMU Munich, Munich, Germany
⁴Department of Medicine III, LMU University Hospital, LMU Munich, Munich, Germany
⁵Department of Infection Immunology, Leibniz-Institute for Natural Product Research and Infection Biology, Jena, Germany
⁶German Cancer Consortium (DKTK) and German Cancer Research Center (DKFZ), Heidelberg, Germany
⁷Department of Medicine III, LMU University Hospital, LMU Munich, Muenchen, Bavaria, Germany

See more of: Oral and Poster Abstracts

<< Previous Session | Next Session >>

^*signifies non-member of ASH

618.O2.6 618. Acute Lymphoblastic Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis: Targeted Therapies and The Immune Microenvironment